Epilepsy is a common neurologic disorder, it is estimated that ∼50 million people are affected worldwide.
About one third of those patients are drug resistant, defined as failure to stop all seizures despite adequate trials of at least 2 appropriate medications.
CBD (cannabidiol) has been shown to be an effective treatment for epilepsy, particularly in reducing the frequency and severity of seizures in people with certain types of epilepsy.
In 2018, the FDA approved a CBD-based medication called Epidiolex for the treatment of two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. Clinical trials showed that Epidiolex significantly reduced the number of seizures in patients with these conditions.
CBD works by interacting with the body's endocannabinoid system, which plays a role in regulating various bodily functions, including mood, pain, and sleep. It is thought that CBD may help to reduce seizures by interacting with certain receptors in the brain and nervous system.
There has been an enormous interest in developing antiepileptic drugs with novel mechanisms of action. This review discusses the evidence supporting the anticonvulsant properties of cannabis in humans, focusing on cannabidiol.